Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc V.AVCR

Alternate Symbol(s):  AVCRF

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Bullboard Posts
Comment by kingposton Mar 21, 2015 5:57pm
269 Views
Post# 23547586

RE:USE RX AS A MODEL!!

RE:USE RX AS A MODEL!!
yixter wrote: RX certainly hasn't been diluting their stock to.get where they are so why would we? Yes we have far more drugs available to sell but who says we have to roll them all out at one time. The only way we should have to do a further dilution is if we are supplying a large chain across more territory and if this becomes the case than who will care about a bit more dilution imagine what that would do to the stock if SHOPPERS OR REXALL signs on it would be epic. No doubt this will happen sooner rather than later.


good post on RX as a model ... but NPH sells generics which is different: The medical community already is fully educated on the original brand product (and so you do not have to sell/educate to doctors) and they just get prescribed as generic equivalents...all generics being equal in most doctors eyes... so very little selling costs to doctors for nph compared to rx which has to educate and sell to the medical community a lot...  NPH selling costs are directed to pharmacies getting them to carry the NPH generic portfolio, and once carried by a pharmacy selling costs are very low.. This is part of the beuty of the NPH model,  since as they add new generics to the portfolio the new generics  just get added to the system have almost zero sales costs....and if that new generic added happens to be a high margin "exclusive" generic , or difficult to make generic, or authorized generic then the high margin  profits drop to the NPH bottom line  ... and that is where things get exciting..

Bullboard Posts